08 September 2020>: Clinical Research
Serum-Soluble ST2 Is a Novel Biomarker for Evaluating Left Atrial Low-Voltage Zone in Paroxysmal Atrial Fibrillation
Zefeng Wang 1ACDE , Liting Cheng 1BCD , Junmeng Zhang 1AD , Zhuo Liang 1CD , Ruiqing Dong 2B , Fei Hang 1B , Xinlu Wang 1B , Ziyu Wang 1B , Yongquan Wu 1AD* , Jie Du 3ADE*DOI: 10.12659/MSM.926221
Med Sci Monit 2020; 26:e926221
Table 5 Comparison of secondary outcomes between sST2 levels.
Group 1 (n=114) | Group 2 (n=63) | P valve | |
---|---|---|---|
No atrial fibrillation, % | 101 (88.6%) | 44 (69.8%) | 0.002 |
Composite outcome events, % | 6 (5.3%) | 5 (7.9%) | 0.481 |
Major adverse events, % | 0 | 0 | |
Rehospitalization, % | 5 (4.0%) | 5 (7.9%) | |
Atrial flutter, % | 5 (4.0%) | 4 (6.3%) | |
Heart failure, % | 0 | 1 (1.6%) |